Advertisement

Advertisement

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • The Nobel Prizes 2024: Learn more about the laureates in Chemistry and Physiology or Medicine and their groundbreaking discoveries, and explore how AI findings are revolutionizing life sciences. Exclusive interviews with Victor Ambros and David Baker.
  • Breaking new ground: Learn more about cutting-edge life science fields like CRISPR and quantum computing. Companies and researchers share their insight.
  • Hot topics: Questions raised around myeloma treatments, a creative approach to the workforce challenge, EU’s legislation labyrinth, and the potential of integrated leadership.
Subscribe now

Opinion & debate

Clinical Trials

Clinical Trials – January 14, 2025

Orexo announces positive topline data

Orexo has announced positive topline results from the clinical study OX640-002.

Clinical Trials – December 18, 2024

Hansa Biopharma announces positive full results

Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.

Clinical Trials – December 11, 2024

Immunovia announces positive outcome of clinical validation

Immunovia has announced the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).

Clinical Trials – December 10, 2024

Modus Therapeutics initiates Phase II study

The first dose has been administered in the company’s Phase II clinical study evaluating the drug candidate sevuparin for the treatment of chronic kidney disease (CKD) with associated anemia.

Clinical Trials – December 3, 2024

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial

The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.

Clinical Trials – November 19, 2024

Modus Therapeutics receives approval to initiate Phase IIa trial for Chronic Kidney Disease

Modus Therapeutics has received approval from the relevant authorities in Italy for its planned Phase IIa clinical trial with sevuparin.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Business – July 22, 2024

A treatment shift? Nordic progress beyond GLP-1

In the wake of the groundbreaking GLP-1 receptor agonists, a number of new obesity treatments and weight management approaches are emerging  – and a few of them come from the Nordic region. Behavior Lifestyle changes are critical for weight loss, even for patients taking the GLP-1 anti-obesity drugs, and we all know that implementing and […]

Drug development – November 19, 2024

Questions raised around myeloma treatments

In Sweden, recent debate and criticism regarding approved multiple myeloma treatments has shone the spotlight on IMiDs and their effects. NLS asked Fredrik Schjesvold, MD, PhD, founder and leader of Oslo Myeloma Center, Oslo University Hospital, about these drugs and the ongoing debate. 

Column – December 10, 2024

Protein, protein, protein!

When it comes to life science, one of the strengths of Norway and the Nordics is basic and translational immunology. This is where researchers engineer cells and soluble proteins with the aim of developing new strategies to treat diseases, such as autoimmunity and cancer. 

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.